A clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. We founded atai Life Sciences in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics. We have built a pipeline of 10 development programs and six enabling technologies, each led by focused teams with deep expertise in their respective fields and supported by our internal development and operational infrastructure.
Lead Underwriter
Berenberg Capital Markets LLC, Citigroup Global Markets Inc, Cowen and Company, LLC, Credit Suisse Securities (USA) LLC
Co-Managers
Canaccord Genuity LLC, Cantor Fitzgerald & Co, RBC Capital Markets, LLC
